Skip to Main Content

Advertisement

American Association for Cancer Research Logo Open Menu
header search
Search
Advanced Search
Skip Nav Destination

Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer

Clin Cancer Res (2010) 16 (24): 6093–6099.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker
  • Caroline Burgard
  • Jakob Engler
  • Arne Blickle
  • Mark Bartholomä
  • Stephan Maus
  • Andrea Schaefer-Schuler
  • Fadi Khreish
  • Samer Ezziddin
  • Florian Rosar
Frontiers in Medicine (2024) 10
SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases
  • Nazanin Zamani-Siahkali
  • Seyed Ali Mirshahvalad
  • Abolfazl Farbod
  • Ghasemali Divband
  • Christian Pirich
  • Patrick Veit-Haibach
  • Gary Cook
  • Mohsen Beheshti
Seminars in Nuclear Medicine (2024) 54 (3): 356.
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
  • Florian Rosar
  • Caroline Burgard
  • Scott David
  • Robert J. Marlowe
  • Mark Bartholomä
  • Stephan Maus
  • Sven Petto
  • Fadi Khreish
  • Andrea Schaefer-Schuler
  • Samer Ezziddin
Scientific Reports (2024) 14 (1)
ACR Appropriateness Criteria® Post-Treatment Follow-up of Prostate Cancer: 2022 Update
  • Baris Turkbey
  • Aytekin Oto
  • Brian C. Allen
  • Oguz Akin
  • Lauren F. Alexander
  • Mim Ari
  • Adam T. Froemming
  • Pat F. Fulgham
  • Lori Mankowski Gettle
  • Jodi K. Maranchie
  • Seth A. Rosenthal
  • Nicola Schieda
  • David M. Schuster
  • Aradhana M. Venkatesan
  • Mark E. Lockhart
Journal of the American College of Radiology (2023) 20 (5): S164.
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging
  • Yuhao Jiang
  • Si’an Fang
  • Junhong Feng
  • Qing Ruan
  • Junbo Zhang
Molecular Pharmaceutics (2023) 20 (1): 630.
Diagnostic Performance of [18F]-Labeled PET/CT Tracers for Lymph Node/Bone Metastasis and Biochemical Recurrence Detection in Advanced Prostate Cancer: A Meta-Analysis
  • YiRui Guo
  • Yu Tian
  • Yuxin Deng
  • ChunMei Lu
  • YanJuan Wang
  • Chunjing Yu
Urologia Internationalis (2022) 106 (11): 1107.
Prognostic role of 11C‐choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy
  • Masaya Jimbo
  • Jack R. Andrews
  • Mohamed E. Ahmed
  • Ayca Dundar
  • R. Jeffrey Karnes
  • Alan H. Bryce
  • Ayse T. Kendi
  • Eugene D. Kwon
  • Val J. Lowe
  • Michael S. Bold
The Prostate (2022) 82 (1): 41.
New index to assess the extent of bone disease in patients with prostate cancer using SPECT/CT
  • Hajime Ichikawa
  • Takayuki Shibutani
  • Masahisa Onoguchi
  • Yuki Taniguchi
Annals of Nuclear Medicine (2022) 36 (11): 941.
A Comprehensive Biological and Synthetic Perspective on 2-Deoxy-d-Glucose (2-DG), A Sweet Molecule with Therapeutic and Diagnostic Potentials
  • Yasanandana S. Wijayasinghe
  • Meenakshi P. Bhansali
  • Maheshkumar R. Borkar
  • Ganesh U. Chaturbhuj
  • Brian S. Muntean
  • Ronald E. Viola
  • Pravin R. Bhansali
Journal of Medicinal Chemistry (2022) 65 (5): 3706.
Synthesis and Evaluation of 11C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography
  • James M. Kelly
  • Thomas M. Jeitner
  • Nicole N. Waterhouse
  • Wenchao Qu
  • Ethan J. Linstad
  • Banafshe Samani
  • Clarence Williams
  • Anastasia Nikolopoulou
  • Alejandro Amor-Coarasa
  • Stephen G. DiMagno
  • John W. Babich
Molecules (2022) 27 (5): 1552.
MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer
  • A. Cannistraci
  • P. Hascoet
  • A. Ali
  • P. Mundra
  • N. W. Clarke
  • V. Pavet
  • R. Marais
Oncogene (2022) 41 (10): 1445.
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study
  • Andreas G. Wibmer
  • Michael J. Morris
  • Mithat Gonen
  • Junting Zheng
  • Hedvig Hricak
  • Steven Larson
  • Howard I. Scher
  • Hebert Alberto Vargas
Journal of Nuclear Medicine (2021) 62 (8): 1050.
The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
  • Kai Shen
  • Bo Liu
  • Xiang Zhou
  • Yiyi Ji
  • Lei Chen
  • Qi Wang
  • Wei Xue
Frontiers in Oncology (2021) 11
Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies
  • Jake Kendrick
  • Roslyn Francis
  • Ghulam Mubashar Hassan
  • Pejman Rowshanfarzad
  • Robert Jeraj
  • Collin Kasisi
  • Branimir Rusanov
  • Martin Ebert
Frontiers in Oncology (2021) 11
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients
  • Matteo Bauckneht
  • Francesco Bertagna
  • Maria Isabella Donegani
  • Rexhep Durmo
  • Alberto Miceli
  • Vincenzo De Biasi
  • Riccardo Laudicella
  • Giuseppe Fornarini
  • Alfredo Berruti
  • Sergio Baldari
  • Annibale Versari
  • Raffaele Giubbini
  • Gianmario Sambuceti
  • Silvia Morbelli
  • Domenico Albano
Prostate Cancer and Prostatic Diseases (2021) 24 (4): 1198.
Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions
  • Ida Sonni
  • Ryogo Minamimoto
  • Lucia Baratto
  • Sanjiv S. Gambhir
  • Andreas M. Loening
  • Shreyas S. Vasanawala
  • Andrei Iagaru
Molecular Imaging and Biology (2020) 22 (2): 397.
Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management
  • Charles Marcus
  • Peter Butler
  • Aditya Bagrodia
  • Suzanne Cole
  • Rathan M. Subramaniam
American Journal of Roentgenology (2020) 215 (2): 267.
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome
  • Salma Meziou
  • Cassandra Ringuette Goulet
  • Hélène Hovington
  • Véronique Lefebvre
  • Étienne Lavallée
  • Michelle Bergeron
  • Hervé Brisson
  • Audrey Champagne
  • Bertrand Neveu
  • Didier Lacombe
  • Jean-Mathieu Beauregard
  • François-Alexandre Buteau
  • Julie Riopel
  • Frédéric Pouliot
Prostate Cancer and Prostatic Diseases (2020) 23 (3): 441.
Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials
  • Jose Mauricio Mota
  • Andrew J. Armstrong
  • Steven M. Larson
  • Josef J. Fox
  • Michael J. Morris
Prostate Cancer and Prostatic Diseases (2019) 22 (4): 522.
Task Group 174 Report: Utilization of [18F]Fluorodeoxyglucose Positron Emission Tomography ([18F]FDG‐PET) in Radiation Therapy
  • Shiva K. Das
  • Ross McGurk
  • Moyed Miften
  • Sasa Mutic
  • James Bowsher
  • John Bayouth
  • Yusuf Erdi
  • Osama Mawlawi
  • Ronald Boellaard
  • Stephen R. Bowen
  • Lei Xing
  • Jeffrey Bradley
  • Heiko Schoder
  • Fang‐Fang Yin
  • Daniel C. Sullivan
  • Paul Kinahan
Medical Physics (2019) 46 (10)
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT
  • Hossein Jadvar
  • Erik M. Velez
  • Bhushan Desai
  • Lingyun Ji
  • Patrick M. Colletti
  • David I. Quinn
Journal of Nuclear Medicine (2019) 60 (11): 1524.
Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8–10 Prostate Cancers Identifies Very High–risk Patients for Early Recurrence and Resistance to Castration
  • Etienne Lavallée
  • Michelle Bergeron
  • François-Alexandre Buteau
  • Annie-Claude Blouin
  • Nicolas Duchesnay
  • Thierry Dujardin
  • Rabi Tiguert
  • Louis Lacombe
  • Vincent Fradet
  • Molière Makao-Nguile
  • Yves Fradet
  • Jean-Mathieu Beauregard
  • Frédéric Pouliot
European Urology Focus (2019) 5 (6): 998.
Molecular Imaging of Recurrent and Metastatic Prostate Cancer
  • Robert E. Ware
  • Scott Williams
  • Rodney J. Hicks
Seminars in Nuclear Medicine (2019) 49 (4): 280.
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
  • Matteo Bauckneht
  • Selene Capitanio
  • Maria Isabella Donegani
  • Elisa Zanardi
  • Alberto Miceli
  • Roberto Murialdo
  • Stefano Raffa
  • Laura Tomasello
  • Martina Vitti
  • Alessia Cavo
  • Fabio Catalano
  • Manlio Mencoboni
  • Marcello Ceppi
  • Cecilia Marini
  • Giuseppe Fornarini
  • Francesco Boccardo
  • Gianmario Sambuceti
  • Silvia Morbelli
Cancers (2019) 12 (1): 31.
ACR Appropriateness Criteria ® Post-treatment Follow-up Prostate Cancer
  • Adam T. Froemming
  • Sadhna Verma
  • Steven C. Eberhardt
  • Aytekin Oto
  • Lauren F. Alexander
  • Brian C. Allen
  • Fergus V. Coakley
  • Brian J. Davis
  • Pat F. Fulgham
  • Keyanoosh Hosseinzadeh
  • Christopher Porter
  • V. Anik Sahni
  • David M. Schuster
  • Timothy N. Showalter
  • Aradhana M. Venkatesan
  • Carolyn L. Wang
  • Erick M. Remer
Journal of the American College of Radiology (2018) 15 (5): S132.
Assessment of Skeletal Tumor Load in Metastasized Castration-Resistant Prostate Cancer Patients: A Review of Available Methods and an Overview on Future Perspectives
  • Francesco Fiz
  • Helmut Dittman
  • Cristina Campi
  • Silvia Morbelli
  • Cecilia Marini
  • Massimo Brignone
  • Matteo Bauckneht
  • Roberta Piva
  • Anna Maria Massone
  • Michele Piana
  • Gianmario Sambuceti
  • Christian La Fougère
Bioengineering (2018) 5 (3): 58.
Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer
  • Kenichi Nakajima
  • Lars Edenbrandt
  • Atsushi Mizokami
International Journal of Urology (2017) 24 (9): 668.
Prospective evaluation of computer-assisted analysis of skeletal lesions for the staging of prostate cancer
  • Lars J. Petersen
  • Jesper C. Mortensen
  • Henrik Bertelsen
  • Helle D. Zacho
BMC Medical Imaging (2017) 17 (1)
3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer
  • Sarah Lindgren Belal
  • May Sadik
  • Reza Kaboteh
  • Nezar Hasani
  • Olof Enqvist
  • Linus Svärm
  • Fredrik Kahl
  • Jane Simonsen
  • Mads H. Poulsen
  • Mattias Ohlsson
  • Poul F. Høilund-Carlsen
  • Lars Edenbrandt
  • Elin Trägårdh
EJNMMI Research (2017) 7 (1)
Multimodality imaging using proton magnetic resonance spectroscopic imaging and18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer
  • Amita Shukla-Dave
  • Cecilia Wassberg
  • Darko Pucar
  • Heiko Schöder
  • Debra A Goldman
  • Yousef Mazaheri
  • Victor E Reuter
  • James Eastham
  • Peter T Scardino
  • Hedvig Hricak
World Journal of Radiology (2017) 9 (3): 134.
Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis
  • Dongyang Li
  • Hang Lv
  • Xuanyu Hao
  • Yudi Dong
  • Huixu Dai
  • Yongsheng Song
Oncotarget (2017) 8 (48): 84449.
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3′-deoxy-3′[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma
  • Kalevi Kairemo
  • Gregory C. Ravizzini
  • Homer A. Macapinlac
  • Vivek Subbiah
Diagnostics (2017) 7 (2): 20.
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between 99mTc-Bone-Scintigraphy and [68Ga]Ga-PSMA PET/CT
  • Lena Thomas
  • Caroline Balmus
  • Hojjat Ahmadzadehfar
  • Markus Essler
  • Holger Strunk
  • Ralph Bundschuh
Pharmaceuticals (2017) 10 (3): 68.
Clinical PET Imaging in Prostate Cancer
  • Kathryn L. Wallitt
  • Sairah R. Khan
  • Suraiya Dubash
  • Henry H. Tam
  • Sameer Khan
  • Tara D. Barwick
RadioGraphics (2017) 37 (5): 1512.
18F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer
  • Werner Langsteger
  • Alireza Rezaee
  • Christian Pirich
  • Mohsen Beheshti
Seminars in Nuclear Medicine (2016) 46 (6): 491.
Is There Use for FDG-PET in Prostate Cancer?
  • Hossein Jadvar
Seminars in Nuclear Medicine (2016) 46 (6): 502.
Bone Scan Index predicts outcome in patients with metastatic hormone‐sensitive prostate cancer
  • Mads H. Poulsen
  • Janne Rasmussen
  • Lars Edenbrandt
  • Poul F. Høilund‐Carlsen
  • Oke Gerke
  • Allan Johansen
  • Lars Lund
BJU International (2016) 117 (5): 748.
Closed intramedullary nailing with percutaneous cement augmentation for long bone metastases
  • Y-i. Kim
  • H. G. Kang
  • J. H. Kim
  • S-k. Kim
  • P. P. Lin
  • H. S. Kim
The Bone & Joint Journal (2016) 98-B (5): 703.
Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers
  • Gurdip Kaur Azad
  • Benjamin Taylor
  • Domenico Rubello
  • Patrick M. Colletti
  • Vicky Goh
  • Gary J. Cook
Clinical Nuclear Medicine (2016) 41 (1): e44.
EXINI Quantitative Bone Scan Index: Expanded Utility for the Planar Radionuclide Bone Scan
  • Steven M. Larson
Journal of Nuclear Medicine (2016) 57 (1): 5.
PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management
  • Abhishek Mahajan
  • Gurdip Kaur Azad
  • Gary J. Cook
PET Clinics (2016) 11 (3): 305.
Serial 18 F-Choline-PET Imaging in Patients Receiving Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: Response Assessment and Imaging Biomarkers
  • Francesca Maines
  • Orazio Caffo
  • Davide Donner
  • Isabella Sperduti
  • Emilio Bria
  • Antonello Veccia
  • Franca Chierichetti
  • Giampaolo Tortora
  • Enzo Galligioni
Future Oncology (2016) 12 (3): 333.
Multi-technique imaging of bone metastases: spotlight on PET-CT
  • Gurdip K. Azad
  • Gary J. Cook
Clinical Radiology (2016) 71 (7): 620.
Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer
  • Hossein Jadvar
Abdominal Radiology (2016) 41 (5): 889.
18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer
  • HAKAN ÖZTÜRK
  • İNANÇ KARAPOLAT
Oncology Letters (2016) 11 (1): 316.
Mise au point sur l’imagerie moléculaire dans le cancer de la prostate
  • L. Michaud
  • K.A. Touijer
Progrès en Urologie (2016) 26 (11-12): 619.
What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer
  • Leslie K. Ballas
  • Andre Luis de Castro Abreu
  • David I. Quinn
Journal of Nuclear Medicine (2016) 57 (Supplement 3): 6S.
PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer
  • Hossein Jadvar
Journal of Nuclear Medicine (2016) 57 (Supplement 3): 25S.
Imaging biomarkers in prostate cancer: role of PET/CT and MRI
  • M. Picchio
  • P. Mapelli
  • V. Panebianco
  • P. Castellucci
  • E. Incerti
  • A. Briganti
  • G. Gandaglia
  • M. Kirienko
  • F. Barchetti
  • C. Nanni
  • F. Montorsi
  • L. Gianolli
  • S. Fanti
European Journal of Nuclear Medicine and Molecular Imaging (2015) 42 (4): 644.
Comparison of NaF and FDG PET/CT for Assessment of Treatment Response in Castration-Resistant Prostate Cancers With Osseous Metastases
  • Urban Simoncic
  • Scott Perlman
  • Glenn Liu
  • Mary Jane Staab
  • Jane Elizabeth Straus
  • Robert Jeraj
Clinical Genitourinary Cancer (2015) 13 (1): e7.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

Resources

AACR Journals
on Social Media

  • Copyright © 2025 by the American Association for Cancer Research.
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal